Reuters logo
BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel
November 14, 2017 / 12:50 PM / 7 days ago

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

Nov 14 (Reuters) - Pacira Pharmaceuticals Inc

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

* Pacira Pharmaceuticals Inc - ‍prescription drug user fee act (PDUFA) goal date for completion of review by FDA of April 6, 2018 remains unchanged​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below